Heart failure program aims for better patient outcomes across Michigan

Participating practices will use the program to monitor and increase the use of recommended heart failure therapies

8:45 AM

Author | Noah Fromson

A graphic says BMC2 Heart Failure with a logo for Michigan medicine and Blue Cross Blue Shield

ANN ARBOR, Mich. -- Cardiovascular care leaders in Michigan will launch a population health program focused on improving the quality of care for patients with heart failure across the state. 

The BMC2 Heart Failure Quality Improvement Program will be led by the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2), a statewide collaborative quality initiative hosted at Michigan Medicine.  It will bring together clinicians and quality partners to identify and eliminate gaps in care using data-driven insights. 

Clinical practices that participate will receive performance benchmarks and feedback to support more consistent delivery of guideline-recommended medical care, with an early focus on heart failure therapies.

“The launch of this program represents a resounding commitment to advancing best practices in heart failure care through cross-center, multidisciplinary collaboration,” said Jessica R. Golbus, M.D., M.S., a heart failure and transplant cardiologist at the University of Michigan Health Frankel Cardiovascular Center and Director of BMC2 Heart Failure. 

“By leveraging data, we can identify opportunities to extend the highest-quality care to a population of patients that is growing in our state.”

More than 6 million Americans are living with heart failure, and that number is projected to reach 10 million by 2040. 

Heart failure occurs when the organ cannot fill with or pump blood effectively enough to meet the body’s needs, most commonly due to coronary artery disease, high blood pressure or heart valve disease.

Nearly half of cases are classified as heart failure with reduced ejection fraction, or HFrEF, meaning the left ventricle cannot pump efficiently.

The program will initially focus on patients with HFrEF, for which effective treatments are available. 

A combination of four guideline-directed medications has been shown to significantly reduce mortality and hospitalizations for HFrEF. However, studies indicate that fewer than 1 in 6 eligible patients receive the full treatment regimen 

“Despite clear evidence of overwhelming benefit to patients, quadruple therapy is rarely prescribed at optimal doses,” Nicholas Osborne, M.D., M.S., the Ramon Berguer, MD, PhD, Research Professor of Vascular Surgery at U-M Medical School and Director of BMC2. 

“Our initial efforts will focus on prescribing lifesaving medical therapies for patients with heart failure with reduced ejection fraction, though these efforts will expand in subsequent years to include all patients with heart failure and to ensure guideline-alignment in areas beyond just medications.”

Heart failure contributed to nearly half of all U.S. cardiovascular deaths in 2022 and accounted for $32 billion in direct medical costs in 2020.

Hospitalizations for heart failure, which are generally higher in HFrEF, made up nearly 40% of those costs. 

Leaders of BMC2 Heart Failure say the work to eliminate gaps in care will reduce hospitalizations, directly lowering costs for patients, clinicians and insurance providers.

“Our program’s Patient Advisory Council will ensure that the patient and caregiver voices remain central throughout implementation by shaping priorities and providing feedback that directly informs improvements to workflows, materials and support pathways,” said Mollie Bodin, M.A., BMC2’s Administrative Director.

In its first year, program leaders will establish a data strategy which will be implemented across five practices in Michigan in the second year. 

Heart failure remains one of the most prevalent and costly chronic conditions facing our healthcare system, requiring a more coordinated, data-driven approach to care,” said Faris Ahmad, M.D., M.B.A., Senior Medical Director at Blue Cross Blue Shield of Michigan.

“Building on the success of BMC2’s proven collaborative registry model, the BMC2 Heart Failure Quality Improvement Program will help hospitals identify care gaps, implement evidence-based best practices, and improve outcomes for patients across Michigan. By supporting more consistent, high-quality care and reducing preventable hospitalizations, this initiative has the potential to deliver meaningful value for patients, providers, and the healthcare system as a whole.”

About BMC2: BMC2 includes the Michigan Cardiac Rehab Network and multi-center quality improvement programs for PCI, vascular surgery, heart failure, and transcatheter valve replacement and repair.

Support for BMC2 is provided by Blue Cross Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program.

Although Blue Cross Blue Shield of Michigan and BMC2 work collaboratively, the opinions, beliefs, and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.

Further, BCBSM does not have access to BMC2 data, and all patient episodes occurring at engaged hospitals are included in the data registries, regardless of payer.

About Michigan Medicine: At Michigan Medicine, we advance health to serve Michigan and the world. We pursue excellence every day in our 12 hospitals and hundreds of clinics statewide, as well as educate the next generation of physicians, health professionals and scientists in our U-M Medical School.

Michigan Medicine includes the U-M Medical School and University of Michigan Health, which includes the C.S. Mott Children’s Hospital, Von Voigtlander Women’s Hospital, University Hospital, the Frankel Cardiovascular Center, Kellogg Eye Center, University of Michigan Health-West, University of Michigan-Sparrow and the Rogel Cancer Center. The U-M Medical School is one of the nation’s biomedical research powerhouses, with total research funding of more than $750 million.

More information is available at www.michiganmedicine.org

About Blue Cross Blue Shield of Michigan: Blue Cross Blue Shield of Michigan, a nonprofit mutual insurance company, is an independent licensee of the Blue Cross and Blue Shield Association. BCBSM provides health benefits to more than 4.7 million members residing in Michigan in addition to employees of Michigan-headquartered companies residing outside the state. The company has been committed to delivering affordable health care products through a broad variety of plans for businesses, individuals and seniors for over 80 years. Beyond health care coverage, BCBSM supports impactful community initiatives and provides leadership in improving health care. For more information, visit bcbsm.com and MiBlueDaily.com.

Featured News & Stories

women looking at model hand in front of poster and computer on table next to them
Health Lab

Rethinking how clinicians learn to feel disease

For most doctors, learning to recognize swollen joints begins in the classroom. A clinical assistant professor in Michigan Medicine's Division of Rheumatology saw a gap in how to distinguish subtle swelling in joints, thus creating a hand simulator to help.
Portrait of Thomas Macek. He's wearing a navy blazer and light blue button-down shirt.
Philanthropy News

College of Pharmacy alum advances U-M Medical School addiction research

Grateful for support that help launched his career in pharmacology research and drug development, Tom Macek, Ph.D., has made a gift to the University of Michigan Medical School to advance addiction research.
mom smiling with two kids
Health Lab

Rare genetic eye disease treated with gene therapy helps 2 children see again

Mia and Niko Spicer were diagnosed with Leber’s congenital amaurosis type 2, a rare genetic eye disease, and were treated with the gene therapy Luxturna to improve their vision.
water color cells black background colorful
Health Lab

How a common virus's hijack of cell repair processes may promote cancer

Researchers at the University of Michigan look at details surrounding EBV’s reactivation from latent infection, known as the lytic phase of viral replication. 
Well-Being at Michigan Medicine with Dr. Elizabeth Harry
Well-Being at Michigan Medicine

Rethinking care: How ‘de-implementation’ can improve quality and reduce burnout

In this episode of Well-Being at Michigan Medicine with Dr. Elizabeth Harry, Dr. Eve Kerr explores the concept of de-implementation—scaling back unnecessary tests, treatments, and administrative hurdles. Kerr shares how eliminating low-value practices can reduce clinician overload, lower patient costs, and improve overall health outcomes. Discover how both healthcare organizations and local frontline teams can foster a culture of high-value care by eliminating outdated processes.
News Release

U-M Board of Regents names C. Cybele Raver as choice for 17th president

U-M Board of Regents names C. Cybele Raver as choice to become University of Michigan president